Krystal Biotech, Inc., (the “Company”) (NASDAQ: KRYS), the leader in redosable gene therapy, today announced that Krish S. Krishnan, Chairman and Chief Executive Officer, will participate in the Bank of America Merrill Lynch Global Healthcare Conference.
Details for the event are as follows:
| Bank of America Merrill Lynch Global Healthcare Conference | ||
| Date: | Tuesday, May 10, 2022 | |
| Time: | 9:20am PDT | |
| Webcast Link: | https://bofa.veracast.com/webcasts/bofa/hc2022/id6InQpA.cfm | |
A webcast of the presentation will be available on the Investors section of the Company’s website for 90 days following the presentation.
About Krystal Biotech
Krystal Biotech, Inc. (NASDAQ: KRYS) is a pivotal-stage gene therapy company leveraging its proprietary, redosable gene therapy platform and in-house manufacturing capabilities to develop life-changing treatment options for patients with serious diseases, including rare diseases in skin, lung, and other areas. For more information, please visit http://www.krystalbio.com and follow @KrystalBiotech on LinkedIn and Twitter.
CONTACT:
Investors and Media:
Meg Dodge
Krystal Biotech
This email address is being protected from spambots. You need JavaScript enabled to view it.
Source: Krystal Biotech, Inc.
| Last Trade: | US$153.22 |
| Daily Change: | 1.14 0.75 |
| Daily Volume: | 325,500 |
| Market Cap: | US$4.430B |
July 09, 2025 | |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
